Clinical Data Lilly debuts more Foundayo data as FDA requests post-marketing trials Pharmaceutical TechnologyThe FDA requires Eli Lilly to evaluate "unexpected serious" risks associated with Foundayo - some of which have been addressed by the ACHIEVE-4 trial.Clinical DataMetabolic & GLP-1Read full story pharminent April 16, 2026 (Last updated: April 16, 2026) Pharmaceutical Technology The FDA requires Eli Lilly to evaluate “unexpected serious” risks associated with Foundayo – some of which have been addressed by the ACHIEVE-4 trial. Clinical DataMetabolic & GLP-1Read full story Post navigation Previous: Roche to start new Elevidys study following setback in EuropeNext: Lilly’s new obesity pill passes heart safety test in diabetes Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026